Intensity Therapeutics Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Intensity Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The company is focused on developing intratumoral cancer therapies using its proprietary non-covalent conjugation technology. The extension is a result of Nasdaq's review of the company's request for an extension to regain compliance with the Minimum Bid Price Requirement.